• We previously demonstrated that chronic pretreatment with a thiazolidinedione peroxisome proliferator-activated receptor (PPAR)-γ activator, troglitazone, improves recovery of left ventricular (LV) function and substrate metabolism after ischemia and reperfusion, without causing arrhythmias. (diabetesjournals.org)
  • Acute treatment with troglitazone increases susceptibility to ventricular fibrillation during myocardial ischemia and reperfusion. (diabetesjournals.org)
  • Subsequent disruption of calcium homeostasis and myocardial remodeling leads to a progressive impairment of ventricular myocyte contractility that may result in heart failure [ 6 - 8 ]. (hindawi.com)
  • Inhibiting fibronectin matrix deposition by pUR4 treatment or by deleting fibronectin gene expression in cardiac fibroblasts confirmed cardioprotection against ischemia reperfusion-induced injury by attenuating at first left ventricular remodeling and cardiac fibrosis, thus preserving cardiac function. (libsyn.com)
  • Ventricular Ectopics and non-sustained VT are very common especially post reperfusion. (abcmedicalnotes.com)
  • Because metabolic control, as indicated by HbA1c values, was comparably improved in both treatment arms, the observed beneficial effects of pioglitazone on cardiovascular risk markers are suggested to be independent from overall metabolic improvement but may rather be direct effects of PPAR{gamma} activation. (natap.org)
  • Current widespread treatments for T2DM include metformin (suppressor of hepatic glucose production), sulfonylureas (insulin secretagogues), and the thiazolidinedione pioglitazone (PPAR agonist). (ddw-online.com)
  • Some of PPARγ agonists (rosiglitazone, pioglitazone) are currently used for the control of type II diabetes [ 2 ]. (e-roj.org)
  • Renal ischemia-reperfusion injury (IRI) is considered as a major cause of acute kidney injury. (frontiersin.org)
  • Renal ischemia-reperfusion injury (IRI) is a common pathophysiological phenomenon in clinical settings. (frontiersin.org)
  • Myocardial ischemic injury is a primary cause of death among various cardiovascular disorders. (bvsalud.org)
  • Restoration of blood supply to ischemic tissue is noted to cause even more lethal reperfusion injury. (bvsalud.org)
  • Various strategies, including some conditioning techniques, like preconditioning and postconditioning, have been developed to check the detrimental effects of reperfusion injury. (bvsalud.org)
  • The article also provides an insight into various clinical studies that substantiate the applicability of adenosine as a cardioprotective agent in myocardial reperfusion injury. (bvsalud.org)
  • Inflammatory signaling in cardiomyocytes usually occurs as an early response to myocardial injury and entails cytosolic and mainly mitochondrial reactive oxygen species (ROS) overproduction [ 10 , 11 ]. (hindawi.com)
  • In today's paper, first author Dr Valiente-Alandi, corresponding author Dr Blaxall from University of Cincinnati College of Medicine and Heart Institute, and their colleagues hypothesized that interfering with fibronectin polymerization, or its genetic ablation and fibroblasts, would attenuate myocardial fibrosis and improve cardiac function following ischemia reperfusion injury. (libsyn.com)
  • Acute kidney injury (AKI) can result from a variety of etiologies (e.g., ischemia, toxicity, and sepsis) and is characterized by high rates of morbidity and mortality. (biolifesas.org)
  • This protective role has been demonstrated in various animal models of ischemia and reperfusion injury such as myocardial infarction, cardioplegia, and renal transplantation.4-11Before the availability of human SOD, clinical studies of SOD in humans were limited to the use of bovine SOD. (docksci.com)
  • Alternating LBBB and RBBB: suggests extensive myocardial injury and high risk of CHB. (abcmedicalnotes.com)
  • These applications include but are not limited to aging, Parkinson's and Alzheimer's diseases, cardiac atrial fibrillation, and ischemia-reperfusion injury. (epiphanyasd.com)
  • In this study, we investigated the role of the NF-κB signaling pathway and inflammation in the amelioration of renal IRI using pioglitazone. (frontiersin.org)
  • In rat renal tissue, pioglitazone treatment decreased the serum levels of post-renal IRI creatinine and urea nitrogen, as well as necrosis. (frontiersin.org)
  • Pioglitazone also decreased the mRNA expression of TNF-α and MCP-1 in the renal tissue. (frontiersin.org)
  • Thus, pioglitazone ameliorates renal IRI by inhibiting the NF-κB signaling pathway and inflammatory response in rats. (frontiersin.org)
  • Therefore, in this study, we aimed to investigate the molecular mechanisms underlying pioglitazone hydrochloride-mediated amelioration of renal IRI with respect to the nuclear factor-kappaB (NF-κB) signaling pathway and inflammatory response using a rat model. (frontiersin.org)
  • We and others have reported that myocardial inflammation develops in human patients and experimental models of type 1 (T1DM) and type 2 (T2DM) diabetes mellitus [ 8 , 14 , 15 ]. (hindawi.com)
  • This prospective randomized controlled trial demonstrates significant improvements of multiple cardiovascular risk markers during treatment with pioglitazone in comparison to glimepiride administration over six months. (natap.org)
  • In conclusion, the presented study gives evidence of an anti-inflammatory and potential antiatherogenic effect of pioglitazone that is indicated by improvements in several traditional and nontraditional cardiovascular risk markers and carotid IMT, independent of an improvement in long-term glycemic control. (natap.org)
  • The Insulin Resistance Intervention after Stroke, or IRIS trial, demonstrated that pioglitazone reduced the risk of both cardiovascular events and diabetes in insulin-resistant patients. (libsyn.com)
  • The microvascular and parenchymal organ damage induced upon ischemia tissue reperfusion is mainly attributed to the reactive oxygen-free radicals, and it has been demonstrated in many organs. (frontiersin.org)
  • In comparison to glimepiride, pioglitazone treatment led to a significant increase in HDL cholesterol and adiponectin, decrease in fasting glucose and insulin, significant higher reduction of triglycerides, and a significant higher reduction in the LDL/HDL ratio. (natap.org)
  • These pronounced differences between pioglitazone and sulfonylurea treatment have been consistently described by several groups in the literature. (natap.org)
  • However, concern remains that pioglitazone may increase the risk of heart failure in susceptible individuals. (libsyn.com)
  • Pioglitazone did not increase the risk of incident heart failure, and the effect of pioglitazone did not differ across levels of baseline risk. (libsyn.com)
  • 15. Statin-induced improvement of endothelial progenitor cell mobilization, myocardial neovascularization, left ventricular function, and survival after experimental myocardial infarction requires endothelial nitric oxide synthase. (nih.gov)
  • [ 43 , 44 ] A therapy with these additional benefits would be invaluable in the treatment of T2D, as many patients with diabetes are also ultimately found to have significant CV disease and are at increased risk of CV events and myocardial infarction (MI). (medscape.com)
  • also reported that infusion of GLP-1 prior to induction of ischemia and reperfusion significantly reduced infarction size compared with saline in both isolated rat hearts and whole animal models. (medscape.com)
  • Myocardial overexpression of TIMP3 after myocardial infarction exerts beneficial effects by promoting angiogenesis and suppressing early proteolysis. (kassirilab.com)
  • Genetic deletion of soluble epoxide hydrolase provides cardioprotective responses following myocardial infarction in aged mice. (kassirilab.com)
  • demonstrated that dogs with dilated cardiomyopathy treated with GLP-1 infusion showed an increase in myocardial glucose uptake and improved left ventricular performance. (medscape.com)
  • Journal Article] Nanoparticle incorporating Toll-like receptor 4 inhibitor attenuates myocardial ischaemia-reperfusion injury by inhibiting monocyte-mediated inflammation in mice. (nii.ac.jp)
  • 1. Prostaglandins mediate the cardioprotective effects of atorvastatin against ischemia-reperfusion injury. (nih.gov)
  • 10. [Cardioprotective effects of atorvastatin preconditioning via iNOS upregulation in a rabbit ischemia/reperfusion model]. (nih.gov)
  • 7. Pioglitazone protects the myocardium against ischemia-reperfusion injury in eNOS and iNOS knockout mice. (nih.gov)
  • These applications include but are not limited to aging, Parkinson's and Alzheimer's diseases, cardiac atrial fibrillation, and ischemia-reperfusion injury. (epiphanyasd.com)
  • 13. Aspirin augments 15-epi-lipoxin A4 production by lipopolysaccharide, but blocks the pioglitazone and atorvastatin induction of 15-epi-lipoxin A4 in the rat heart. (nih.gov)
  • [ 54 ] A pilot study in humans was then published in 2004 reporting a trend towards improved myocardial function in subjects with T2D and New York Heart Association class II and III CHF treated with a 3-day infusion of GLP-1. (medscape.com)
  • 4. Aspirin before reperfusion blunts the infarct size limiting effect of atorvastatin. (nih.gov)